Entrada Therapeutics (TRDA) Stock

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $1.02 per share a year ago.

Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA). “Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical.

- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within the Duchenne community - BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible.

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to loss of $0.78 per share a year ago.

Entrada Therapeutics (TRDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a biopharmaceutical company focused on developing innovative medicines that target intracellular pathways previously thought to be unreachable. CEO Dipal Doshi will be speaking at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ in New York City on May 20, 2024 at 9:30 a.m. ET.

Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.

Entrada Therapeutics shares plummeted almost 30% after it announced that the U.S. Food and Drug Administration (FDA) has refused to lift its clinical hold on its Phase 1 study of its investigational therapeutic ENTR-601-44 for Duchenne muscular dystrophy.